These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20149590)

  • 41. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 42. Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.
    Camporota L; Corno E; Menaldo E; Smith J; Lei K; Beale R; Wyncoll D
    Crit Care; 2008; 12(6):R163. PubMed ID: 19094233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.
    Levy M; Levi M; Williams MD; Antonelli M; Wang D; Mignini MA
    Intensive Care Med; 2009 Jul; 35(7):1196-203. PubMed ID: 19367397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock.
    Mehta NJ; Khan IA; Gupta V; Jani K; Gowda RM; Smith PR
    Int J Cardiol; 2004 May; 95(1):13-7. PubMed ID: 15159032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 46. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.
    Macias WL; Vallet B; Bernard GR; Vincent JL; Laterre PF; Nelson DR; Derchak PA; Dhainaut JF
    Crit Care Med; 2004 Dec; 32(12):2385-91. PubMed ID: 15599140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure.
    La Vecchia L; Mezzena G; Zanolla L; Paccanaro M; Varotto L; Bonanno C; Ometto R
    J Heart Lung Transplant; 2000 Jul; 19(7):644-52. PubMed ID: 10930813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
    Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
    Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 51. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 52. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
    Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
    Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Raised serum cardiac troponin I concentrations predict hospital mortality in intensive care unit patients.
    Reynolds T; Cecconi M; Collinson P; Rhodes A; Grounds RM; Hamilton MA
    Br J Anaesth; 2012 Aug; 109(2):219-24. PubMed ID: 22617093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
    Chawla LS; Seneff MG; Nelson DR; Williams M; Levy H; Kimmel PL; Macias WL
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):22-30. PubMed ID: 17699383
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality.
    Eggers KM; Lagerqvist B; Venge P; Wallentin L; Lindahl B
    Circulation; 2007 Oct; 116(17):1907-14. PubMed ID: 17909103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac troponin I as a prognostic factor in critically ill pneumonia patients in the absence of acute coronary syndrome.
    Lee YJ; Lee H; Park JS; Kim SJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    J Crit Care; 2015 Apr; 30(2):390-4. PubMed ID: 25534985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac findings in asymptomatic chronic hemodialysis patients with persistently elevated cardiac troponin I levels.
    Katerinis I; Nguyen QV; Magnin JL; Descombes E
    Ren Fail; 2008; 30(4):357-62. PubMed ID: 18569907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drotrecogin alfa (activated) treatment of older patients with severe sepsis.
    Ely EW; Angus DC; Williams MD; Bates B; Qualy R; Bernard GR
    Clin Infect Dis; 2003 Jul; 37(2):187-95. PubMed ID: 12856210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.
    Gentry CA; Gross KB; Sud B; Drevets DA
    Crit Care Med; 2009 Jan; 37(1):19-25. PubMed ID: 19050637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.